Definitive Contract HHSN272200900060C
Award Date
8/15/09
Potential Completion Date
8/14/14
Potential Value
$101M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Netherlands
Solicitation Procedures
Basic Research
Number Of Offers Received
35
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $93,164,303.39 cost plus fixed fee definitive contract awarded by the U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization, on September 14, 2015. The contract has an ultimate completion date of August 16, 2024 and is not set-aside. The contract is for products and services related to HHS's preparedness and response programs, though...
<p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services' National Institutes of Health (DHHS NIH) to Janssen Vaccines & Prevention B.V., a foreign-owned, for-profit organization, for the production of adenoviral vector vaccines. The contract has a potential value of $82,806,174.12 and a completion date of September 14, 2011. The contract is not set aside for any specific business type. The award is not associated with a larger vehicle. The contract is...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Sanofi Pasteur Biologics, LLC, a foreign-owned for-profit organization. The contract is for the development and testing of a modified vaccinia Ankara (MVA) vaccine, with a ceiling value of $12,667,339.96. The contract is a definitive, cost-plus-fixed-fee contract type, with a final completion date of January 8, 2007. The...
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), for research and development facilities. The definitive contract, with a ceiling value of $151,614,235.06, was awarded on September 27, 2001 and has an ultimate completion date of October 31, 2011. The contract type is Cost No Fee, and there was no set-aside used. The place of performance is Potomac, Maryland. Without...
This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...
This is a federal contract award to Sanofi Pasteur Inc., a foreign-owned, for-profit manufacturer of goods, to provide research and development facilities. The contract, valued at $8,045,553.00, is a definitive contract without a set-aside designation, with an ultimate completion date of December 30, 2009. The funding agency is the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. In addition to this contract, Sanofi...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to JPT Peptide Technologies GMBH, a foreign-owned for-profit manufacturer of custom peptides and related research products. The $3,620 firm fixed price purchase order is for the delivery of peptide microarrays displaying peptides from a previous order, in support of NIAID's research activities. The award has no set-aside...